Stryker Corporation $SYK Holdings Lowered by JLB & Associates Inc.

JLB & Associates Inc. reduced its stake in Stryker Corporation (NYSE:SYK) by 18.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,723 shares of the medical technology company’s stock after selling 4,979 shares during the period. JLB & Associates Inc.’s holdings in Stryker were worth $6,839,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in SYK. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter worth approximately $26,000. Sankala Group LLC bought a new position in Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker during the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker during the 4th quarter valued at $28,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

NYSE SYK opened at $331.96 on Wednesday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The business’s fifty day moving average is $325.56 and its two-hundred day moving average is $333.05. The stock has a market capitalization of $127.33 billion, a P/E ratio of 34.40, a P/E/G ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Analysts Set New Price Targets

A number of research firms have recently commented on SYK. Raymond James Financial set a $370.00 price objective on Stryker in a research note on Friday, July 31st. Piper Sandler decreased their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Citizens Jmp dropped their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Finally, Royal Bank Of Canada cut their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 315,370 shares of company stock worth $98,463,501 in the last quarter. 4.60% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.